Generate Biomedicines (GENB) CTO granted new stock option awards

Rhea-AI Filing Summary

Generate Biomedicines Chief Technology Officer Gevorg Grigoryan reported two grants of stock options to acquire company shares. One option covers 295,608 shares and vests in two equal installments on February 19, 2029 and February 19, 2030, subject to continued service. A second option covers 196,368 shares and vests in forty-eight equal monthly installments following February 19, 2026, also conditioned on his continued service. Both awards are recorded at an exercise price of $0.00 per share, reflecting their nature as compensatory grants rather than open-market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Grigoryan Gevorg

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	295,608	$0.00	--
Grant/Award	Stock Option (Right to Buy)	196,368	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 295,608 shares (Direct)

Footnotes (1)

1. The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grigoryan Gevorg

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		295,608		(1)	02/25/2036	Common Stock	295,608	$0	295,608	D
Stock Option (Right to Buy)	$16	02/26/2026		A		196,368		(2)	02/25/2036	Common Stock	196,368	$0	196,368	D

Explanation of Responses:

1. The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GENB's CTO report on this Form 4?

Generate Biomedicines’ CTO, Gevorg Grigoryan, reported receiving two stock option grants. One covers 295,608 shares and another 196,368 shares, both at a $0.00 exercise price, reflecting equity-based compensation rather than open-market buying or selling activity.

How many stock option shares were granted to the GENB CTO?

The CTO received options over 295,608 shares in one grant and 196,368 shares in another. Each grant is recorded as a direct award, giving him rights to buy Generate Biomedicines shares under the specified vesting schedules and conditions.

What are the vesting terms for the 295,608-share option grant at GENB?

The 295,608-share option grant vests in two equal installments on February 19, 2029 and February 19, 2030. Vesting on each date is subject to Gevorg Grigoryan’s continued service with Generate Biomedicines through the applicable vesting date.

How does the 196,368-share stock option grant at GENB vest?

The 196,368-share stock option grant vests in forty-eight equal monthly installments following February 19, 2026. Each monthly vesting tranche requires the CTO to continue serving at Generate Biomedicines on the applicable vesting date to receive that portion.

Were the GENB CTO’s stock options acquired through market purchases?

No. Both stock option positions were acquired as grants with a $0.00 exercise price per share. They are compensatory awards, not open-market purchases, and become exercisable only as the stated vesting conditions tied to continued service are satisfied.

Does this GENB Form 4 indicate any insider share sales?

The filing shows no reported sales by the CTO. It reflects two derivative transactions coded as awards or other acquisitions (Code A), representing newly granted stock options rather than dispositions of existing Generate Biomedicines common stock holdings.